ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
StrideBio Logo

StrideBio

Our mission is to develop best-in-class gene therapies for people with life-threatening diseases. Our vision is to be the leader in the evolution of gene therapy and be known for superior drug development, high industry standards, extraordinary integrity and an innovative team that translates science into treatments that prolong and improve lives.

Quick overview

Durham, United States

Founded in 2015

51-100 Employees

Medium-Sized

Additional information

Working industry

Biotechnology

Type of company

Manufacturer

Ownership structure

Privately Held

Locations

1 Headquarter

Number of products

7 Products

Number of services

2 Services

Specialised areas

Scientific Research and Development Services, Professional, Scientific, and Technical Services, Gene Therapy, Therapeutics, AAV Vectors, Biotechnical research, commercial, Biotechnology, Information Technology, Health Care

Products & services of StrideBio

StrideBio offers a wide range of products and services

Product: StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform - StrideBio

Product

StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform - StrideBio

Go to product >

Product: Our Approach - StrideBio

Product

Our Approach - StrideBio

Go to product >

Product: StrideBio Appoints Maritza McIntyre, Ph.D., as Chief Development Officer - StrideBio

Service

StrideBio Appoints Maritza McIntyre, Ph.D., as Chief Development Officer - StrideBio

Go to product >

Product: StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - StrideBio

Product

StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - StrideBio

Go to product >

Product: CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement - StrideBio

Service

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement - StrideBio

Go to product >

Product: Construct Design and Manufacturing - StrideBio

Product

Construct Design and Manufacturing - StrideBio

Go to product >

Product: StrideBio Secures Seed Funding to Advance its Novel AAV Platform - StrideBio

Product

StrideBio Secures Seed Funding to Advance its Novel AAV Platform - StrideBio

Go to product >

Product: Capsid Platform - StrideBio

Product

Capsid Platform - StrideBio

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Use Cases of StrideBio

Get insights into the use cases of StrideBio

UseCase: CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio - StrideBio

Use case

CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio - StrideBio

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for developing CRISPR-based therapeutics in select disease areas, today announced they have signed a collaboration agreement with StrideBio, LLC, a US-based company developing novel AAV vectors for in vivo gene delivery applications.

Headquarter of StrideBio

StrideBio operates in 1 country around the world

City: Durham

State: North Carolina

Country: United States

Locations of StrideBio

Get an overview of the locations of StrideBio

Location

Country

State

City

Headquarter

United States

North Carolina

Durham

Frequently asked questions (FAQ) about StrideBio

Some frequent questions that have been asked about StrideBio

The company headquarter of StrideBio is located in Durham, North Carolina, United States. It's worth noting, that the company may have more locations

As of the latest available information StrideBio has around 51-100 employees worldwide.

StrideBio was founded in 2015

The company StrideBio has it's main focus in the industries of Biotechnology

Based on the founding year and the amount of employees the company StrideBio seems to be a Medium-Sized at the current state. Note that over time that status can change

Competitors of StrideBio

Check out some interesting alternative companies to StrideBio

Kriya Therapeutics's Logo

Kriya Therapeutics

Palo Alto, United States

51-100 Employees

2019

We are developing life-changing gene therapies for conditions affecting millions of people around the world. Our mission is to make gene therapies accessible – not just for the few – but for the many. We are located in Palo Alto, California and Research Triangle Park, North Carolina. We are backed by leading healthcare and technology investors who are committed to our goal of building the world’s leading gene therapy biopharmaceutical company. We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits.

GenSight Biologics's Logo

GenSight Biologics

Paris, France

11-50 Employees

2012

Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system. We are proud of the two promising product candidates that, to date, have advanced to the stage of being tested in clinical trials. Our goal: to transform the lives of patients suffering from severe degenerative diseases of the eye and central nervous system. Our gene therapy-based approach appeals to us not just because we are excited about bringing advanced, innovative science to bear on diseases with a severe impact on patients’ quality of life. Thus, our two leading product candidates are currently designed to be administered in a single treatment to each eye by intravitreal, or IVT, injection. We believe that our technology platforms have wide applicability, not just within ophthalmology but outside as well, potentially to other disorders of the central nervous system. Even as we push forward on getting our lead products to market, our research teams are exploring gene therapy-based therapy options for other neurodegenerative conditions for which no satisfactory solutions have been found.

Jaguar Gene Therapy's Logo

Jaguar Gene Therapy

Lake Forest, United States

11-50 Employees

2019

We are driven by our mission to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. We are focused on moving gene therapy solutions from bench to bedside as safely and rapidly as possible. We are targeting some of the most devastating genetic diseases with significant unmet medical need: diseases in which gene therapies can have transformational impact on the lives of patients and those who care for them. Our mission is to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. We are rapidly advancing an initial pipeline of gene therapies for serious diseases with major unmet needs in sizable patient populations. At Jaguar Gene Therapy, we believe in a world where individuals living with severe genetic diseases are no longer told there are no treatment options that can change the trajectory of their lives. We believe in a world where these same people receive medicines at the earliest stage of their diseases. We believe in a world where long-lasting, one-time treatments are possible.

Scopus BioPharma's Logo

Scopus BioPharma

New York, United States

1-10 Employees

2018

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.

Life Edit's Logo

Life Edit

Morrisville, United States

11-50 Employees

2017

We are scientific pioneers with unlimited potential to cure genetic disease. We are scientists and leaders on a shared mission to make innovative, curative therapies available to patients with devastating genetic diseases. We are guided by curiosity, rigor, and integrity. We are pioneers with unlimited potential to cure genetic disease. Our highly innovative, next-generation platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. They were developed from a proprietary collection of non-pathogenic organisms and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Life Edit Therapeutics has joined ElevateBio’s portfolio of therapeutic, technology, and manufacturing companies and reimagined our identity. Our brand is an expression of our values, mission, and commitment to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable.

Spark Therapeutics's Logo

Spark Therapeutics

Philadelphia, United States

51-100 Employees

2013

Our mission at Spark Therapeutics is to unlock the power of gene therapy to accelerate healthcare transformation. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations.